argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and…
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Favorable safety and tolerability profile, with rapid onset of clinical activity and…
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied…
Philips announces exchange ratio for 2025 dividend
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the…
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
Exceptional track record across multiple clinical development programs for depression, three of…
Nanobiotix Joins the Euronext Tech Leaders Index
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext:…
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrm Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
June 01, 2026 08:05 ET | Source: Cellectar Biosciences, Inc. Approximately 80%…
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation…
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone…
